After identifying the targeted nerves, the company’s radiofrequency ablation technology is employed to ablate the nerves. Credit: MAD.vertise / Shutterstock.com.
The European Patent Office (EPO) has granted patent no. 3,697,298 to Autonomix Medical’s catheter-based technology that facilitates the gathering and analysis of sensory data, essential for real-time physiological monitoring in various medical scenarios.
The patent titled ‘Medical Device with Circuitry for Capturing and Processing Physiological Signals’ covers a broad spectrum of applications, including arterial and renal mapping, coronary artery and vagal nerve mapping, as well as bladder and lower urinary tract applications.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is also applicable to central nervous system monitoring for neurotherapy and the operation of robotic implants and prosthetics.
At the heart of the patent is a system composed of distributed signal acquisition modules that enhance the integrity of signal capture while performing neural mapping procedures.
These modules are integrated along the catheter for capturing, amplifying, digitising and transmitting physiological signals from the associated sensors locally.
The technology incorporates several integral components, such as multiple processing modules linked to one or more sensors, data acquisition logic, and comprehensive signal processing circuitry that includes both analogue and digital components positioned at the source of the signals.
Additionally, it features data transmission capabilities and a modular microchip design and offers technical advantages, including miniaturisation, heightened precision and reduced noise interference.
Autonomix noted that its catheter-based microchip sensing array antenna is designed to identify and distinguish neural signals with a level of sensitivity that surpasses existing technologies.
After identifying the targeted nerves, the company’s radiofrequency (RF) ablation technology is employed to ablate these nerves, enabling a targeted approach.
This method applies to a range of diseases, from chronic pain management to hypertension and cardiology.
Autonomix Medical CEO Brad Hauser said: “The ‘298 patent combined with 80 other issued patents positions us to capture opportunities across multiple multi-billion-dollar markets, create diverse revenue streams, and expand our global footprint as we advance toward potential commercialisation in the future.”
Last year, Autonomix reported preliminary outcomes from a trial that assessed the use of transvascular RF ablation in the management of pain associated with pancreatic cancer.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.